Abstract

Regulatory Issues for the Use of Bulk Drugs in Veterinary Compounding

Author(s): Chan Debora Schotik

Issue: Mar/Apr 2001 - Compounding for Animals

Page(s): 97-100

Download in electronic PDF format for $75

Abstract

Regulations for the use of bulk drugs in animals are unclear. In this article, the author focuses on US food and drug regulations, use of bulk drugs to compound for humans and animals, US Food and Drug Administration regulations governing the use of bulk drugs, and regulatory actions. Tables provide a list of proposed bulk drugs suitable for use in compounding for humans, drug products not to be used in compounding and drugs prohibited for extralabel use in food-producing animals.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Mar/Apr 2003 Pg. 106-113	Veterinary Transdermal Medications: A to Z Author(s): Davidson Gigi S
Jul/Aug 2015 Pg. 303-305	U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Author(s): Miller David G
Mar/Apr 2001 Pg. 97-100	Regulatory Issues for the Use of Bulk Drugs in Veterinary Compounding Author(s): Chan Debora Schotik
Sep/Oct 2017 Pg. 356	PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Author(s): Allen Loyd V Jr
Jan/Feb 2017 Pg. 19-21	When to Compound Medications for Veterinary Patients Author(s): Forsythe Lauren Eichstadt
Jul/Aug 2016 Pg. 351 View Sample	Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Author(s): Allen Loyd V Jr
Nov/Dec 2016 Pg. 457-458	U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List) Author(s):
Sep/Oct 2021 Pg. 358-362	Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA Author(s): Cabaleiro Joe
Nov/Dec 2015 Pg. 487-488	U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Author(s): Allen Loyd V Jr
May/Jun 2005 Pg. 201-205	Combating Cardiovascular Disease with Compounded Medications -- Part 2: Clinical and Compounding Issues for Antihypertensive Drugs Author(s): Harrington Catherine A, Cauffield Jacintha
Nov/Dec 2002 Pg. 434-437	Regulatory and Operational Issues of Founding a Compounding Pharmacy Author(s): Smith Lisa K
Jan/Feb 2020 Pg. 30-36	Quality Control: Personal Protective Equipment for Use When Handling Hazardous Drugs Author(s): Dillon L R
Jan/Feb 2023 Pg. 22-23	The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone Author(s): Brunner Scott
Nov/Dec 2006 Pg. 446-448	Basics of Compounding for Hazardous Drugs, Part 2: Regulation and Sources of Contamination Author(s): Allen Loyd V Jr
Nov/Dec 2012 Pg. 456-460	Drug Shortage Compounding: The Only Safe Medication Source in a Time of Crisis Author(s): Lyon Joanna
Sep/Oct 2014 Pg. 379-380	Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A Author(s): Blankenship Cynthia E
Sep/Oct 2015 Pg. 389-390	Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1 Author(s): Allen Loyd V Jr
May/Jun 2004 Pg. 181-185	Compounding in the Pharmacy Curriculum: Beyond the Basics Author(s): Hinkle Amanda R, Newton Gail D
Jan/Feb 2005 Pg. 44-46	The US FDA List of Drugs Not to Be Used in Compounded Medications for Humans (the "Negative List") Author(s): Allen Loyd V Jr, Ashworth Lisa D
Nov/Dec 2023 Pg. 474-481	Nonsterile Basics of Compounding: Using U.S. Food and Drug Administration-approved Commercial Products as Ingredients Author(s): Allen Loyd V Jr